Ebglyss — lebrikizumab
Named-patient access overview. Ebglyss is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Ebglyss
Ebglyss (lebrikizumab) is manufactured by Lilly and indicated for Atopic dermatitis. It is a IL-13 mAb approved by the US FDA in 2024 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Ebglyss
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Ebglyss for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Ebglyss is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
We have documented named-patient access pathways for Ebglyss in the countries below. Each page outlines the destination-country regulatory posture, typical timeline, and physician-credential requirements.
Ebglyss in BahrainNamed-patient access, timeline, and regulatory notes
Ebglyss in BangladeshNamed-patient access, timeline, and regulatory notes
Ebglyss in IndiaNamed-patient access, timeline, and regulatory notes
Ebglyss in JordanNamed-patient access, timeline, and regulatory notes
Ebglyss in OmanNamed-patient access, timeline, and regulatory notes
Ebglyss in PakistanNamed-patient access, timeline, and regulatory notes
Ebglyss in QatarNamed-patient access, timeline, and regulatory notes
Ebglyss in Sri LankaNamed-patient access, timeline, and regulatory notes
Start a request for Ebglyss
Submit a 60-second intake. Our clinical team responds within one business day with case-specific feasibility, timeline, and a formal quote.